Sell Drugs: Innovation Special

In a new wave of innovations, yesterday, 20,000 jobs were innovated in R&D at Beezer Pharmaceuticals.



Divisions mostly affected by the innovations include clinical research, global marketing and 'back room functions'. "We're delighted to see this kind of innovation driven into the organisation," said Fenk Teemaker, CEO. "The new culture established by these innovations will pay significant dividends in the long run, as we look to add shareholder value. We have been very public with our commitment to innovation, and I can't think of a greater way to signal this commitment than to innovate these roles with immediate effect. We're innovating way harder and way faster than any of our competitors."

In the Reuters press release, Beezer Corporate Communications added: "There is no stronger culture of innovation than one where every employee wonders whether they will have a role next week. In that kind of a culture, innovation drives every waking moment. Most importantly, when we deliver on that promise of innovation, our share price goes up, so our investors clearly agree."

Jon Stone, a scientist formerly with the Discovery and Translational Science group at Beezer, described his innovation with heavy heart. "As soon as they started talking innovation publicly, we knew that the swords were dangling. It is always hard to await the innovation email, or that call from your boss, knowing that you're the next innovation. When I called my wife, and told her that I'd been innovated, she cried - innovation is no respecter of 25 years of commitment."